IBEX 35
11.105,50 +55,40 (+0,50%) Euro Stoxx 50
5.085,08 +30,67 (+0,61%) Dólar/Euro
1,0772 -0,0012 (-0,11%) Petróleo Brent
82,73 -1,15 (-1,37%) Oro
2.366,90 +26,60 (+1,14%) Bitcoin EUR
56.472,00 -0,06 (-0,00%)
NANO MRNA Co.,Ltd. (3NQ.F)
NANO MRNA Co.,Ltd.
Atago Green Hills MORI Tower
26th Floor 2-5-1 Atago Minato-ku
Tokyo
Japan
81 3 6432 4791
https://www.nanomrna.co.jp
Sector(es): Healthcare
Sector: Biotechnology
Empleados a tiempo completo: 17
Ejecutivos clave
| Nombre | Título | Paga | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. Atsushi Matsumura | Executive Chairman of the Board | N/A | N/A | 1962 |
| Dr. Shiro Akinaga Ph.D. | President, CEO, CSO, MD of R&D Division and Director | N/A | N/A | 1956 |
| Mr. Koji Fujimoto | CFO, MD of Corporate Division & Director | N/A | N/A | 1972 |
Descripción
NANO MRNA Co.,Ltd. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company's pipeline products include RUNX1 (mRNA) for the treatment in the area of tissue generation and vaccines; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers Complex, an antibacterial ear drops; cosmetic raw material, and platelet-rich therapy. The company was formerly known as NanoCarrier Co., Ltd. and changed its name to NANO MRNA Co.,Ltd. in June 2023. NANO MRNA Co.,Ltd. was incorporated in 1996 and is headquartered in Tokyo, Japan.
Gobierno corporativo
El ISS Governance QualityScore de NANO MRNA Co.,Ltd., a día N/A, es N/A. Las puntuaciones base son Auditoría: N/A; Tablero: N/A; Derechos de los accionistas: N/A; Compensación: N/A.
